Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
暂无分享,去创建一个
R. Barst | D. Badesch | A. Frost | V. McLaughlin | V. Tapson | R. Oudiz | L. Rubin | S. Murali | R. Channick | H. Hsu
[1] C. Ricachinevsky,et al. Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.
[2] M. Hoeper,et al. Pulmonary arterial hypertension: the race for the most effective treatment. , 2005, American journal of respiratory and critical care medicine.
[3] R. Barst,et al. Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.
[4] T. Welte,et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension , 2004, European Respiratory Journal.
[5] M. Humbert,et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.
[6] A. Torbicki,et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. , 2004, Journal of the American College of Cardiology.
[7] M. Hoeper,et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids , 2003, European Respiratory Journal.
[8] W. Seeger,et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[9] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[10] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[11] G. Simonneau,et al. New treatments for pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.
[12] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[13] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[14] T. Kaptchuk. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? , 2001, Journal of clinical epidemiology.
[15] M. Hoeper,et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.
[16] W. Seeger,et al. Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial , 2000, Annals of Internal Medicine.
[17] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[18] W. Seeger,et al. Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension , 1996, Annals of Internal Medicine.
[19] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[20] M. Pillinger,et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .
[21] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[22] Orris,et al. INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .